Company: BOLT
Filing Date: 2025-10-02
Form Type: 8-K
Source: 0001193125-25-228293
Chunk: 1

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-10-02
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events

On October 1, 2025, the Company announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach. As a result of the update to the clinical trial protocol for BDC-4182, the Company now expects to report initial clinical data in the third quarter of 2026. To conserve capital and maintain long-term shareholder value, the Company is implementing a workforce reduction as described in Item 2.05, extending its cash runway into 2027. A press release announcing the reduction-in-force described in Item 2.05 and the update on the ongoing Phase 1 dose escalation study of BDC-4182 is filed hereto as Exhibit 99.1.

  Exhibit No.      Description                                                                   
         99.1      Press Release dated October 1, 2025.                                          
 ─────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document).  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                           Bolt Biotherapeutics, Inc.                                      
  Date:      October 2, 2025      By:      /s/ William P. Quinn                                            
                                           William P. Quinn